Sens. Rand Paul (R-KY) and Cory Booker (D-NJ) (Olivier Douliery/Sipa USA/Sipa via AP Images)

Con­gress takes an­oth­er look at re­clas­si­fy­ing psilo­cy­bin and MD­MA

Months af­ter Sens. Cory Book­er (D-NJ) and Rand Paul (R-KY) in­tro­duced a bill that would ex­pand ac­cess to Sched­ule I drugs for ter­mi­nal­ly ill pa­tients, the law­mak­ers are tak­ing an­oth­er stab.

Book­er and Paul on Thurs­day in­tro­duced a new bill called the Break­through Ther­a­pies Act, which would al­low the Drug En­force­ment Ad­min­is­tra­tion to make the nec­es­sary find­ings to re­clas­si­fy break­through ther­a­pies such as MD­MA or psilo­cy­bin as Sched­ule II drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.